CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Stemcell Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Stemcell Holdings Inc
Omotesando Helene Clinic 3-18-17-6F
MINATO-KU, TKY  107-0062  Japan Ticker: STMMSTMM

This company ceased filing statements with the SEC on 5/2/2019.

Business Summary
Stemcell Holdings, Inc. is engaged in the regenerative medicine-related business, which provides technical assistance to the culturing, storing and delivery of stem cells, administrative and consulting services to clinics. The Company provides two options for stem cell regenerative therapy: autologous adipose derived mesenchymal stem cells (ADMSC) and natural killer cells (NK). The Company provides coordination services to facilitate its stem cell culturing business. Its coordination services include the introduction of patients to clinics, arranging patients’ schedules, and translating between patients and clinics. The Company offers Internet marketing services by providing search engine optimization for clinics. It also offers property and equipment rental services. The Company operates through its wholly owned subsidiary, Stemcell Co., Ltd.
(Source: 10-K)

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/201812/31/2017YesYes---

Industries
SIC Code Description
2836 Biological products, except diagnostic substances

Officers and Directors

Title

Name

Age
Title
Date
Start
Date
President, CEO, Secretary, Treasurer and Director TakaakiMatsuoka

Business Names
Business Name
Perfect Acquisition, Inc.
Stemcell Co., Ltd.
STMM

General Information
Outstanding Shares: 427,378,000 (As of 12/31/2022)
Stock Exchange: OTC


Copyright © 2023 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, December 29, 2023